Incyte Corp
Change company Symbol lookup
Select an option...
INCY Incyte Corp
CGNX Cognex Corp
INTC Intel Corp
ZSANQ Zosano Pharma Corp
BIPC Brookfield Infrastructure Corp
UTG Reaves Utility Income Trust
ARDLF Ardent Leisure Group Ltd
BFS Saul Centers Inc
ABB Abb Ltd
BURL Burlington Stores Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.

Closing Price
$74.13
Day's Change
0.40 (0.54%)
Bid
--
Ask
--
B/A Size
--
Day's High
74.95
Day's Low
73.28
Volume
(Below Average)
Volume:
1,291,741

10-day average volume:
1,508,909
1,291,741

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.